Trial · NCT04142190
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time of pronuclei disappearance | 16-18 hours after fertilization | Time of pronuclei disappearance in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON |
| Primary | Two discrete cells | 26-28 hours after fertilization | The first observation of two discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON |
| Primary | Three discrete cells | 28-44 hours after fertilization | The first observation of three discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON |
| Primary | Four discrete cells | 44-45 hours after fertilization | The first observation of four discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON |
| Primary | Five discrete cells | 44-68 hours after fertilization | The first observation of five discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON |
| Primary | Six discrete cells | 44-68 hours after fertilization | The first observation of six discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON |
| Primary | Seven discrete cells | 44-68 hours after fertilization | The first observation of seven discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON |
| Primary | Eight discrete cells | 68-69 hours after fertilization | The first observation of eight discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON |
| Primary | Nine discrete cells | 69-92 hours after fertilization | The first observation of nine discrete cells in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON |
| Primary | Morula stage | 92 hours after fertilization | End of the compaction process; when observable compaction is complete in embryos of patients stimulated with ELONVA versus embryos of patients stimulated with PUREGON |
| Secondary | Number of oocytes retrieved | Number of oocytes retrieved will be evaluated after one treatment cycle (each cycle is between 28 and 35 days) | The influence of ELONVA versus PUREGON on the number of oocytes retrieved will be assessed. |
| Secondary | Stage of oocyte development | Stage of oocytes retrieved will be evaluated after one treatment cycle (each cycle is between 28 and 35 days) | The influence of ELONVA versus PUREGON on the maturity stage of oocytes (germinal vesicle, metaphase I (MI) or MII phase) retrieved will be assessed. |
| Secondary | Fertilized oocytes | Number of fertilized oocytes will be evaluated after one treatment cycle (each cycle is between 28 and 35 days) | The influence of ELONVA versus PUREGON on the number of fertilized oocytes will be assessed. |
| Secondary | Embryo grading | The quality of embryos will be evaluated after one treatment cycle (each cycle is between 28 and 35 days) | The influence of ELONVA versus PUREGON on embryo grading (Istanbul consensus criteria) will be assessed. The grading consists of assessment of cell number, fragmentation, multinucleation, cell size, cytoplasmic granularity, membrane appearance, and the presence of vacuoles). |
| Secondary | Biochemical pregnancy (measurement of beta hCG) | Biochemical pregnancies will be evaluated after successful implantation (1 week after embryo transfer) | The influence of Elonva versus Puregon on the number of biochemical pregnancies will be assessed. |
| Secondary | Life birth | Life births will be evaluated after successful pregnancy (9 moths after embryo transfer) | The influence of Elonva versus Puregon on the number of life births will be assessed. |
| Secondary | Weight (kilograms) | Weight of the newborn will be evaluated after birth (9 moths after embryo transfer) | The influence of Elonva versus Puregon on the weight of the newborn will be assessed. |
| Secondary | Height (centimeters) | Height of the newborn will be evaluated after birth (9 moths after embryo transfer) | The influence of Elonva versus Puregon on the height of the newborn will be assessed. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04142190/registered